Ohno T, Abe M, Tateishi A, Kako K, Miki H
J Bone Joint Surg Am. 1975 Apr;57(3):397-404.
One hundred and thirty patients with osteogenic sarcoma were studied clinically, roentgenographically, and pathologically. Prognosis by each of ten factors was analyzed with the Wilcoxon test. The test yielded p smaller than 0.05 in a comparison between the survival curves of patients fifteen years old or younger and that of patients over fifteen, but other comparisons did not yield p smaller than 0.05. The actual five-year survival rate was 25.5 per cent (twenty-six of 102 patients who had radical surgery). Our therapeutic regimen for osteogenic sarcoma at the present time consists of regional perfusion, amputation, bronchial artery infusion, and systemic administration of anticancer agents.
对 130 例骨肉瘤患者进行了临床、X 线及病理研究。采用 Wilcoxon 检验分析了十个因素中每个因素对预后的影响。在 15 岁及以下患者与 15 岁以上患者的生存曲线比较中，该检验得出的 p 值小于 0.05，但其他比较未得出 p 值小于 0.05 的结果。实际五年生存率为 25.5%（102 例行根治性手术的患者中有 26 例）。我们目前治疗骨肉瘤的方案包括区域灌注、截肢、支气管动脉灌注及全身抗癌药物给药。
